文献速递泌尿男性生殖肿瘤

GRANT评分在ASSURE试验人群中验证预测肾细胞癌预后

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
PubMed 文献 · Ann Oncol · 2017-01-01

研究基于Fuhrman分级、年龄、病理淋巴结状态和病理肿瘤大小构建简易GRANT评分,在ASSURE辅助治疗试验的肾细胞癌患者中外部验证。评分0或1个因素为 favorable risk,2个及以上为 unfavorable risk。新模型性能与已有验证评分系统相似,优势在于计算简便快捷。

要点

  • GRANT评分基于Fuhrman分级、年龄、病理淋巴结状态和病理肿瘤大小四个易得参数。
  • 0或1个危险因素为favorable risk,2个及以上为unfavorable risk。
  • 在ASSURE试验人群中外部验证,性能与已有评分系统相似。

核心结论

  • GRANT评分在ASSURE试验人群中展示出临床应用的潜在价值。

研究设计与样本

  • 基于四个易得参数构建简易GRANT评分,利用ASSURE辅助治疗试验的肾细胞癌患者人群作为独立数据集进行外部验证。

主要发现

  • 新模型性能与已有验证评分系统相似,优势在于计算简便清晰、临床使用快捷。

关键数值与推荐

  • GRANT评分参数:Fuhrman分级、年龄、病理淋巴结状态、病理肿瘤大小。
  • 0或1个因素为favorable risk,2个及以上为unfavorable risk。

临床怎么用

  • GRANT评分计算简便快捷,可能有助于临床实践中的预后评估。

局限性

  • 使用Fuhrman核分级,对罕见组织学类型不适用。
  • TNM分类随时间发生修改。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prognostic scores have been developed to estimate the risk of recurrence and the probability of survival after nephrectomy for renal cell carcinoma (RCC). The use of these tools, despite being helpful to plan a customized schedule of follow-up, to the patient's tailored counselling and to select individuals who could potentially benefit from adjuvant treatment, currently is not routine, due to their relative complexity and to the lack of histological data (i.e. necrosis). PATIENTS AND METHODS: We developed a simple score called GRade, Age, Nodes and Tumor (GRANT) based on four easily obtained parameters: Fuhrman grade, age, pathological nodal status and pathological tumor size. Patients with 0 or 1 factor are classified as favorable risk, whereas patients with two or more risk factors as unfavorable risk. The large population of RCC patients from the ASSURE adjuvant trial was used as independent dataset for this external validation, to investigate the prognostic value of the new score in terms of disease-free survival and overall survival and to evaluate its possible application as predictive tool. Statistical analyses were carried out by the Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute (Boston, USA) for the ASSURE trial patients' population. RESULTS: The performance of the new model is similar to that of the already validated score systems, but its strength, compared with the others already available, is the ease and clarity of its calculation, with great speed of use during the clinical practice. Limitations are the use of the Fuhrman nuclear grade, not valid for rare histologies, and the TNM classification modifications over time. CONCLUSION: The GRANT score demonstrated its potential usefulness for clinical practice. CLINICALTRIALS.GOV IDENTIFIER FOR THE ASSURE TRIAL: NCT00326898.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Buti S, Puligandla M, Bersanelli M, et al. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol. 2017. PMID: 28945839. doi:10.1093/annonc/mdx492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。